AXL mediates resistance to cetuximab therapy - Wikidata - wikimedia - TriplyDB

AXL mediates resistance to cetuximab therapy

AXL mediates resistance to cetuximab therapy

http://www.wikidata.org/entity/Q34204829

about

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas The Receptor Tyrosine Kinase AXL in Cancer Progression Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy Targeting the TAM Receptors in Leukemia The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels.Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib.Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression.AXL is an oncotarget in human colorectal cancer.Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells.Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize.A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer.Regulated intramembrane proteolysis of the AXL receptor kinase generates an intracellular domain that localizes in the nucleus of cancer cells.Sunitinib activates Axl signaling in renal cell cancer.Tyro3 carboxyl terminal region confers stability and contains the autophosphorylation sites.Fisetin, a dietary phytochemical, overcomes Erlotinib-resistance of lung adenocarcinoma cells through inhibition of MAPK and AKT pathways.Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.Giving AXL the axe: targeting AXL in human malignancy.Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck.Axl and Mer Receptor Tyrosine Kinases: Distinct and Nonoverlapping Roles in Inflammation and Cancer?Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL.Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity Axl Receptor Axis: A New Therapeutic Target in Lung Cancer.Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells.MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer.Overcoming resistance to cetuximab with honokiol, a small-molecule polyphenol.Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma.Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation.Function of Axl receptor tyrosine kinase in non-small cell lung cancer.Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.In Silico Approach to Identify Potential Inhibitors for Axl-Gas6 Signaling.TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition.Engineering Axl specific CAR and SynNotch receptor for cancer therapy.Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?

P2860

Q24336818-2ECF7E17-5442-407F-A4A0-6FF2CB50DF5E Q28068756-0D5B8B72-CCD4-48A4-8F03-4CEC252180BA Q28070028-4371B1F6-EB2B-47D2-BE29-DEB6881C9C6F Q28078654-0EBFC287-EB10-4C32-AA50-5A8E98C2FD89 Q35750117-807A703D-EB39-48B9-A6D1-3C50EB0FE131 Q35775881-7C8045EE-FA05-4772-9136-3EABF2A58970 Q35832327-33A330E7-7696-4601-8C1A-62E7CA7BC066 Q35995940-6C57DD8C-A002-4700-80D4-980EEC7DD8A2 Q36414168-25545B6E-7183-4285-8990-C1047AFE5D4B Q36932683-0C1D69BD-0F87-4B1F-A5FC-B55FC1B1DBC8 Q36970393-F5497926-95FD-42C1-9B5A-CDC3140361DF Q37274810-3B7E913F-F72F-4581-992C-2BF24EC549B4 Q37329842-EF659842-83E9-4B8E-BF77-3FA3249947EE Q37665524-2CBEC55F-1736-478F-A663-2F93C7230C94 Q37699039-3A782F71-2FA8-4E55-98A0-AA35C728C943 Q38451761-4C656D5C-0893-487A-9EF3-F04EC75EE8FB Q38698452-97191034-C33C-44C8-A88B-DCAEC7734BD6 Q38728165-FCC99E6E-CE50-49DC-8119-E0631E04727E Q38757863-1722AC7D-D055-402A-9E46-17769484664B Q38772267-E28804ED-0313-4155-8478-AD42E8299BDB Q38854471-8C0FCD32-B2A4-4F02-921C-1FC8EEC95386 Q38877945-89D49B95-09F7-47C2-9C57-2F0DBA09D710 Q38936702-9FE10B8B-4AE3-4770-A44B-24A3DD45A765 Q39157476-4481A6DF-DDC3-4C37-A950-4B35D2AE4183 Q41847773-310B2443-8743-4292-8F55-8B944E5818BA Q41940444-C97B30F2-6A61-4E1F-9C8B-EF553886A54F Q41953242-F353763D-93D9-477E-A240-79D41AFC2BE6 Q42365122-8E5421CB-F136-43C4-8D85-F27DAF6F53F8 Q43246838-3DD0C19D-70BB-4A0E-9DB4-CA4B0CA58675 Q46278768-46F8284F-7142-4103-ADFD-859614CD6E69 Q47130146-A9010C46-BE04-4A98-8FC3-8358B0E016DA Q47203450-EF9F964B-CCBA-46CB-ADCE-D2C3018334D2 Q48070194-1B836DC6-AC52-4AF6-AEAF-FDDD8960415A Q49636410-B3BF8096-B871-4763-A1C3-127A885F6FA2 Q49843607-1008137B-59CF-49B1-B1AE-03733E43FD2B Q51004850-03411B8C-914E-47E4-A256-2D2DE1E60016 Q51263290-3BF1053E-9D5C-47BD-82F1-AA0724624943 Q53814929-9F1DDB62-DA3E-484D-9899-910871C799E6 Q54123522-CE25B159-676C-4303-8399-A016ABE82F8D Q54297620-86308605-92E5-4A6E-8963-5B6C8686FBA2

P2860

AXL mediates resistance to cetuximab therapy

http://www.wikidata.org/entity/Q34204829

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

AXL mediates resistance to cetuximab therapy

@ast

AXL mediates resistance to cetuximab therapy

@en

AXL mediates resistance to cetuximab therapy

@nl

type

label

AXL mediates resistance to cetuximab therapy

@ast

AXL mediates resistance to cetuximab therapy

@en

AXL mediates resistance to cetuximab therapy

@nl

prefLabel

AXL mediates resistance to cetuximab therapy

@ast

AXL mediates resistance to cetuximab therapy

@en

AXL mediates resistance to cetuximab therapy

@nl

P1433

Q34204829-5754AF73-4308-4011-9C86-350F3B7761C2

P1476

Q34204829-A374BD1B-99B9-48DD-A30D-2FFFBC589C9E

P2093

Q34204829-0A033435-43E3-4FD2-B6E8-4B9D0B3F87BA

Q34204829-1A111900-A8E8-4A2F-B813-A6AEE18ADC03

Q34204829-4154DE09-7937-408D-854C-28E4D41CA210

Q34204829-4635F037-5692-4D45-8C2B-A6E98D297832

Q34204829-4F0C0B96-9CB1-4087-B035-6AAD81C1FB00

Q34204829-7FFD4A89-4C65-4F9A-B190-84A206EC2C0A

Q34204829-867304AF-E4B0-4919-85FB-7E589748E593

Q34204829-CA41B26C-B545-4C44-9F81-4E5D7CC72863

Q34204829-F04B36F3-C191-4661-86A9-A7A21A0313C1

Q34204829-FDF3F14E-9892-46C3-B6E4-DD46880D7F59

P2860

Q34204829-06127CFA-48AA-4702-8619-0C7DF1857B77

Q34204829-06AC9BEF-57E2-4A19-AB84-4E7D972A3B03

Q34204829-07241B27-4EC9-496D-9B5A-AC3385192CFC

Q34204829-0A842EBE-C5EC-4F86-8CB4-D8B1DD0ABBE4

Q34204829-0ED922E3-A9A6-42E2-9076-8DD14B8E975B

Q34204829-16F76FB0-0B04-4486-8A4F-167C06CF0F21

Q34204829-17DB8A11-BCCB-41CA-BD98-92709B6FEE40

Q34204829-212C0DC9-0625-4130-84FB-E0799F375748

Q34204829-234237A8-A9AF-4104-A6D9-9F688933F1D0

Q34204829-24DFD17D-73A9-44DE-ADA8-302863EE12A7

P304

Q34204829-6740F33E-0682-4061-88F6-7EF3B59FAD91

P31

Q34204829-C3F77716-58F1-4ADC-A88E-C28B16C9A11D

P356

Q34204829-FD3CB53D-2BC9-4972-90E4-42519C898F5E

P407

Q34204829-3BC6142F-BE7A-4DB1-B69F-CEDE543344C3

P433

Q34204829-532E4127-0F02-4E27-8790-B60A919C6026

P478

Q34204829-30335D12-EAD7-4193-B547-95F43973ED8A

P50

Q34204829-BD1BC20C-57F2-4866-972A-9A5CCA8FD690

P577

Q34204829-4BCC885D-7ECB-4998-83B8-DA97004A3528

P698

Q34204829-58183A35-A33C-4835-B4DD-79C0E7F751D1

P921

Q34204829-9833E125-0E3C-426C-81D4-7BE0E846B609

P932

Q34204829-BAE461E1-22ED-4958-A26C-E824E3056C68

P356

0008-5472.CAN-14-0294

P1433

Cancer Research

P1476

AXL mediates resistance to cetuximab therapy

@en

P2093

Andrew P Stein

http://www.w3.org/2001/XMLSchema#string

Cara M Braverman

http://www.w3.org/2001/XMLSchema#string

Deric L Wheeler

http://www.w3.org/2001/XMLSchema#string

Kelsey L Corrigan

http://www.w3.org/2001/XMLSchema#string

Mahmoud Toulany

http://www.w3.org/2001/XMLSchema#string

Mari Iida

http://www.w3.org/2001/XMLSchema#string

Neha Luthar

http://www.w3.org/2001/XMLSchema#string

Parkash S Gill

http://www.w3.org/2001/XMLSchema#string

Randall J Kimple

http://www.w3.org/2001/XMLSchema#string

Toni M Brand

http://www.w3.org/2001/XMLSchema#string

P2860

Patient-derived tumor xenografts: transforming clinical samples into mouse models

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma.

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

The EGFR as a target for anticancer therapy--focus on cetuximab.

P304

5152-5164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-14-0294

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25136066

http://www.w3.org/2001/XMLSchema#string

P921

P932

4167493

http://www.w3.org/2001/XMLSchema#string